Phase 3 N=197 Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Vasculitis · Wegener's Granulomatosis · Microscopic Polyangiitis
Primary: Disease Remission — 63; 52 Participants — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Phase 3 N=105 Belimumab in Remission of VASculitis
Vasculitis
Primary: Time to First Relapse — NA; NA Days — p=0.884
Phase 3 N=170 Rituximab Vasculitis Maintenance Study
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Microscopic Polyangiitis · Wegener Granulomatosis
Primary: Relapse-free Survival — 38; 60; 13; 32 participants
Phase 2 N=45 Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 3 N=331 A Phase 3 Clinical Trial of CCX168 (Avacopan) in Patients With ANCA-Associated Vasculitis
ANCA-Associated Vasculitis
Primary: Percentage of Subjects Achieving Disease Remission at Week 26 — 70.1; 72.3 percentage of participants — p=< 0.0001
Phase 2 N=42 Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
ANCA-associated Vasculitis
Primary: Incidence of Adverse Events — 13; 11; 15 Participants
Phase 4 N=20 Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Complete Remission — 14 Participants
Phase 2 N=24 Rituximab to Treat Hepatitis C-Associated Cryoglobulinemic Vasculitis
Hepatitis C · Vasculitis
Primary: Percent of Patients in Remission — 83; 8 percent of participants
Phase 4 N=70 Vascular Inflammation in Psoriasis - Apremilast
Psoriasis · Cardiovascular Diseases
Primary: Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. — -0.017 ratio — p=0.612
Phase 2 N=67 A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
Vasculitis
Primary: Proportion of Subjects Achieving Disease Response at Day 85 — 0.7; 0.86; 0.81 proportion of participants
Phase 4 N=43 Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
Psoriasis · Cardiovascular Disease
Primary: Change in Vascular Inflammation — -0.1015; 0.1442; -0.0151 TBR max — p=0.0012
Phase 2 N=25 A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Granulomatosis With Polyangiitis
Primary: Percentage of Participants With Adverse Events (AEs), Including Serious AEs — 100; 100; 28; 48 percentage of participants
Phase 2 N=50 Crizanlizumab for Treating COVID-19 Vasculopathy
COVID-19
Primary: Soluble P-selectin Level — 7; 39 ng/mL
N/A N=165 Validation of a Diagnostic Algorithm of Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of CDU False-positive Patients — 73; 63; 0; 29 Participants
Phase 2 N=83 Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 3 N=58 Inflammation and Vascular Function in Atherosclerosis
Atherosclerosis
Primary: Flow-mediated, Endothelium-dependent Vasodilation — 6.8; 8.7 percentage vasodilation
Phase 3 N=704 Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis
Granulomatosis With Polyangiitis (Wegener's) (GPA) · Microscopic Polyangiitis (MPA)
Primary: Composite of i) All-cause Mortality or ii) End-stage Renal Disease — 100; 109 Participants
Phase 2 N=65 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
N/A N=97 An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Participants With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Granulomatosis With Polyangiitis · Microscopic Polyangiitis
Primary: Incidence Rate of Serious Infections — 7.11 events per 100 patient year
Phase 2 N=50 Study Effect of VIA-2291 on Atherosclerotic Vascular Inflammation in Patients Undergoing Elective Carotid Endarterectomy
Atherosclerosis
Primary: Percent Cross-sectional Area of Macrophages in Plaque Tissue — 8.08; 8.19 Percent Area — p=0.97
N/A N=80 Anti-neutrophil Cytoplasmic Antibody in Interstitial Lung Disease.
Interstitial Lung Disease · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Primary: Death From All Causes — 10; 5 Participants
Phase 2 N=24 Etanercept and Vascular Function in Psoriasis
PSORIASIS
Primary: Vascular Function as Measured by Brachial Artery Flow-mediated Dilation (FMD) — 9.71; 11.15 percentage of brachial artery diameter
Phase 2 N=52 Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Acute Coronary Syndrome
Primary: Change From Baseline in Plaque Imaging After 24 Weeks — -0.01; -0.06 TBR — p=0.34
Phase 2 N=57 Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Granulomatosis With Polyangiitis (GPA) · Microscopic Polyangiitis (MPA)
Primary: Percentage of Subjects Achieving Clinical Response — 16; 22; 10 Participants
Phase 2 N=18 Crizanlizumab for Treatment of Retinal Vasculopathy With Cerebral Leukoencephalopathy (RVCL)
RVCL - Retinal Vasculopathy Cerebral Leukoencephalopathy
Primary: Change in the Percentage of White Matter Hyperintensity (WMH) Lesion Volume on FLAIR MRI in RVCL Patients — 31.3 Percent (%)
N/A N=34 Vasculera in Participants With Lipedema
Lipedema
Primary: Change in Weight From Baseline — 0.340 kilograms — p=0.473
Phase 4 N=36 MIcrovascular dysfuNction In Moderate-severe Psoriasis
Psoriasis · Cardiovascular Disease
Primary: Change in Global Coronary Flow Reserve (CFR) After 6 Months of Therapy With Tildrakizumab — -0.03 CFR Ratio